Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077933 | 0.91 | P2RX1 (0.56) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL26075815 | 0.81 | P2RX1 (0.59) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL26075667 | 0.80 | SORT1 (0.48) | LCKKDRTEK | |
| SCHEMBL29537581 | 0.79 | MEN1 (0.67) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL20577892 | 0.79 | P2RX1 (0.60) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL25231718 | 0.79 | MEN1 (0.67) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL5496719 | 0.79 | RXFP1 (0.60) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL17660212 | 0.77 | TLR8 (0.54) | P2RX1P2RX4P2RX7TMPRSS4SMN1; SMN2 | |
| SCHEMBL29448774 | 0.76 | RXFP1 (0.71) | P2RX1LCKKDRTEKPTGS1 | |
| SCHEMBL19233279 | 0.76 | RXFP1 (0.71) | P2RX1LCKKDRTEKPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | P2RX1 1108/4885LCK 55/4885KDR 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.